These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 18310816

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Contribution of bone quality to fracture risk].
    Mori S.
    Clin Calcium; 2004 Oct; 14(10):33-8. PubMed ID: 15577129
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
    Stepan JJ, Alenfeld F, Boivin G, Feyen JH, Lakatos P.
    Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819
    [Abstract] [Full Text] [Related]

  • 4. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z.
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G, Kriegman A, Gonçalves J, Kianifard F, Warren M, Simon JA.
    Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066
    [Abstract] [Full Text] [Related]

  • 8. [Effects of SERMs on bone health. Effects of raloxifene and bisphosphonate on bone quality in osteoporosis: collagen cross-links, mineralization, and bone strength].
    Saito M.
    Clin Calcium; 2010 Mar; 20(3):345-54. PubMed ID: 20190364
    [Abstract] [Full Text] [Related]

  • 9. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
    Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Evidence of raloxifene on postmenopausal osteoporosis].
    Okano H.
    Nihon Rinsho; 2007 Nov 28; 65 Suppl 9():374-80. PubMed ID: 18161135
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management.
    Felsenberg D, Boonen S.
    Clin Ther; 2005 Jan 28; 27(1):1-11. PubMed ID: 15763602
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis.
    Brandi ML.
    Curr Med Res Opin; 2010 Nov 28; 26(11):2553-63. PubMed ID: 20858031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.